Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$20.27 -0.4%	$20.45	$13.30 ▼ $30.03	$1.21B	0.93	419,198 shs	589,226 shs
FHTX Foghorn Therapeutics	$5.06 +1.0%	$5.31	$2.94 ▼ $10.25	$283.21M	3.05	93,259 shs	77,547 shs
PGEN Precigen	$4.51 -0.9%	$2.10	$0.65 ▼ $4.82	$1.36B	1.87	16.92 million shs	9.09 million shs
XERS Xeris Biopharma	$7.83 -0.9%	$5.81	$2.48 ▼ $8.02	$1.28B	0.65	3.56 million shs	1.51 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	-1.55%	+2.62%	+1.44%	+14.13%	-9.11%
FHTX Foghorn Therapeutics	-7.39%	-0.60%	-15.23%	+21.01%	-34.08%
PGEN Precigen	-0.87%	+25.00%	+189.81%	+244.70%	+302.65%
XERS Xeris Biopharma	-1.13%	+4.08%	+58.00%	+60.24%	+183.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELVN Enliven Therapeutics	2.6183 of 5 stars	3.5	2.0	0.0	2.0	4.2	0.0
FHTX Foghorn Therapeutics	2.8988 of 5 stars	3.6	3.0	0.0	2.9	1.7	0.6
PGEN Precigen	3.8428 of 5 stars	3.4	0.0	4.7	3.0	1.7	0.6
XERS Xeris Biopharma	3.5268 of 5 stars	1.4	3.0	4.2	4.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELVN Enliven Therapeutics	3.00	Buy	$41.20	103.26% Upside
FHTX Foghorn Therapeutics	3.17	Buy	$10.67	110.80% Upside
PGEN Precigen	2.80	Moderate Buy	$8.25	82.93% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$7.08	-9.54% Downside

Current Analyst Ratings Breakdown

Latest FHTX, XERS, PGEN, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PGEN Precigen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/19/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$6.00 ➝ $8.00
8/19/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.50
8/19/2025	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $9.00
8/15/2025	PGEN Precigen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
8/13/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
8/12/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$8.25 per share	N/A
FHTX Foghorn Therapeutics	$24.17M	11.83	N/A	N/A	($1.36) per share	-3.72
PGEN Precigen	$3.92M	342.82	N/A	N/A	($0.12) per share	-37.58
XERS Xeris Biopharma	$203.07M	6.23	N/A	N/A	($0.12) per share	-65.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELVN Enliven Therapeutics	-$89.02M	-$2.00	N/A	N/A	N/A	N/A	-29.15%	-27.88%	11/12/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.19	N/A	N/A	N/A	-311.90%	N/A	-28.00%	11/3/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.42	N/A	N/A	N/A	-2,868.66%	-842.83%	-78.98%	11/13/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.21	N/A	N/A	N/A	-13.01%	N/A	-8.00%	11/14/2025 (Estimated)

Latest FHTX, XERS, PGEN, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A
8/12/2025	Q2 2025	PGEN Precigen	-$0.14	-$0.11	+$0.03	-$0.09	$0.67 million	$0.86 million
8/7/2025	Q2 2025	XERS Xeris Biopharma	-$0.03	-$0.01	+$0.02	-$0.01	$64.58 million	$67.71 million
8/5/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	$7.62 million	$7.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELVN Enliven Therapeutics	N/A	32.58	32.58
FHTX Foghorn Therapeutics	N/A	2.62	2.62
PGEN Precigen	N/A	2.71	2.71
XERS Xeris Biopharma	N/A	1.95	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELVN Enliven Therapeutics	95.08%
FHTX Foghorn Therapeutics	61.55%
PGEN Precigen	33.51%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
ELVN Enliven Therapeutics	25.90%
FHTX Foghorn Therapeutics	7.58%
PGEN Precigen	47.10%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELVN Enliven Therapeutics	50	59.24 million	43.89 million	Optionable
FHTX Foghorn Therapeutics	120	56.53 million	52.25 million	Optionable
PGEN Precigen	190	297.97 million	157.63 million	Optionable
XERS Xeris Biopharma	290	161.48 million	151.03 million	Optionable

FHTX, XERS, PGEN, and ELVN Headlines

Recent News About These Companies

Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue

August 29 at 6:53 AM | uk.finance.yahoo.com

Walleye Capital LLC Invests $3.80 Million in Xeris Biopharma Holdings, Inc. $XERS

August 29 at 5:20 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. $XERS Holdings Raised by Jump Financial LLC

August 29 at 5:19 AM | marketbeat.com

Vanguard Group Inc. Purchases 210,581 Shares of Xeris Biopharma Holdings, Inc. $XERS

August 28 at 3:12 AM | marketbeat.com

Stonepine Capital Management LLC Sells 80,052 Shares of Xeris Biopharma Holdings, Inc. $XERS

August 26 at 7:38 AM | marketbeat.com

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

August 25, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, Leerink Partners Analyst Says

August 24, 2025 | marketbeat.com

FY2025 EPS Estimates for Xeris Biopharma Boosted by Analyst

August 24, 2025 | marketbeat.com

Nuveen LLC Buys New Shares in Xeris Biopharma Holdings, Inc. $XERS

August 24, 2025 | marketbeat.com

Cetera Investment Advisers Buys New Shares in Xeris Biopharma Holdings, Inc. $XERS

August 24, 2025 | marketbeat.com

Q3 EPS Estimates for Xeris Biopharma Decreased by Analyst

August 23, 2025 | marketbeat.com

FY2025 EPS Estimate for Xeris Biopharma Increased by Analyst

August 23, 2025 | americanbankingnews.com

Q3 EPS Estimates for Xeris Biopharma Lowered by Analyst

August 23, 2025 | americanbankingnews.com

Voss Capital LP Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS

August 21, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.58 Average PT from Analysts

August 20, 2025 | americanbankingnews.com

Deutsche Bank AG Grows Position in Xeris Biopharma Holdings, Inc. $XERS

August 19, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Rating of "Moderate Buy" by Analysts

August 18, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson Sells 107,500 Shares

August 17, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week High - Here's Why

August 17, 2025 | marketbeat.com

John Johnson Sells 107,500 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

August 16, 2025 | insidertrades.com

HC Wainwright Estimates Xeris Biopharma Q3 Earnings

August 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, XERS, PGEN, and ELVN Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

$20.27 -0.09 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$20.27 0.00 (0.00%)

As of 04:20 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Foghorn Therapeutics NASDAQ:FHTX

$5.06 +0.05 (+1.00%)

Closing price 04:00 PM Eastern

Extended Trading

$4.96 -0.11 (-2.08%)

As of 06:09 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Precigen NASDAQ:PGEN

$4.51 -0.04 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$4.62 +0.12 (+2.55%)

As of 07:59 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Xeris Biopharma NASDAQ:XERS

$7.83 -0.07 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$7.60 -0.23 (-2.99%)

As of 07:47 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time